AlkermesALKS +4.26%70 Days Payable is 155.82 as of Mar. 2026, which is 61% above its 10-year median of 96.86. GuruFocus rates ALKS with a GF Score™ of 70/100 and a GF Value™ of $31.33 (Significantly Overvalued). The stock has 8 warning signs investors should review. Among 923 Drug Manufacturers companies, Alkermes ranks better than 75.62% on this metric.
Alkermes's average Accounts Payable for the
three
months ended in Mar. 2026 was $105 Mil. Alkermes's Cost of Goods Sold for the
three
months ended in Mar. 2026 was $62 Mil.
Hence, Alkermes's Days Payable for the
three
months ended in Mar. 2026 was 155.82.
The historical rank and industry rank for Alkermes's Days Payable or its related term are showing as below:
ALKS'
s Days Payable Range Over the Past 10 Years
Min: 71.04 Med: 96.86 Max: 152.88
Current: 152.88
During the past 13 years, Alkermes's highest Days Payable was 152.88. The lowest was 71.04. And the median was 96.86.
ALKS's Days Payable is ranked better than 75.62% of 923
companies
in the Drug Manufacturers industry
Industry Median: 90.98
vs ALKS: 152.88
Alkermes's Days Payable
increased
from Mar. 2025 (97.81) to Mar. 2026 (155.82).
It may suggest that Alkermesdelayed paying its suppliers.
Alkermes Days Payable Related Terms
Alkermes Days Payable Historical Data
* Premium members only.
The historical data trend for Alkermes's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Alkermes's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Alkermes Days Payable vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Alkermes's Days Payable distribution charts can be found below:
* The bar in red indicates where Alkermes's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Alkermes's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Alkermes (ALKS) has a Days Payable of 155.82 as of Mar. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Alkermes and its competitors. This is 61% above median its historical median of 96.86. Over the past decade, Alkermes' Days Payable has ranged from 71.04 to 152.88. According to the industry distribution chart, Alkermes ranks #225 out of 923 companies in the Drug Manufacturers industry, placing it in the top 24.4%.
Is Alkermes' Days Payable too high?
Alkermes' current Days Payable of 155.82 is 61% above median its 10-year median of 96.86. Over the past 10 years, this metric has ranged from a low of 71.04 to a high of 152.88. The Drug Manufacturers industry median Days Payable is 90.98. Alkermes' value of 155.82 is 71.3% above this industry median. Based on the distribution chart, Alkermes ranks #225 out of 923 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Alkermes has a GF Score™ of 70/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Alkermes' Days Payable compare to LNTH and HIMS?
According to the Drug Manufacturers industry distribution chart, Alkermes ranks #225 out of 923 companies for Days Payable. This places Alkermes in the top 24% of its industry — outperforming the majority of peers. The industry median Days Payable is 90.98. Alkermes' value of 155.82 is 71.3% above this benchmark. Historically, Alkermes' own Days Payable has ranged from 71.04 to 152.88 over the past decade. While the company's 10-year median is 96.86 vs. the industry median of 90.98, Alkermes has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Drug Manufacturers company?
The median Days Payable among Drug Manufacturers companies is 90.98, based on 923 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Alkermes's current Days Payable of 155.82 is 71.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Alkermes and its competitors. For the Drug Manufacturers industry, the median Days Payable is 90.98 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Alkermes's current Days Payable is 155.82, which is 61% above median its own 10-year median of 96.86. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Alkermes stock overvalued right now?
Based on GuruFocus' analysis, Alkermes (ALKS) is currently considered Significantly Overvalued. The stock's GF Value™ is $31.33, compared to a current price of $55.16 — trading 76% above its estimated fair value. The current Days Payable is 155.82, which is 61% above median its 10-year median of 96.86 and 71.3% above the Drug Manufacturers industry median of 90.98. Alkermes' overall GF Score™ is 70/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Alkermes (ALKS), the current Days Payable is 155.82 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Alkermes (ALKS) Overvalued in 2026?
Based on GuruFocus' analysis, Alkermes stock appears to be overvalued.
The current stock price of $55.16 is trading 76% above its estimated GF Value™ of $31.33.
GuruFocus considers Alkermes to be Significantly Overvalued.
Key valuation signals for ALKS:
Days Payable: 155.82 (61% above median its 10-year median of 96.86)
GF Value™: $31.33 vs. price of $55.16 (76% above fair value)
Industry Position: 71.3% above the Drug Manufacturers median (#225 of 923)
No single metric tells the full story. See the ALKS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Alkermes PLC is a fully integrated biotechnology company that applies its proprietary technologies to research, develop, and commercialize pharmaceutical products designed for unmet medical needs in therapeutic areas. The company utilizes several to develop and commercialize products and, in so doing, access technological, financial, marketing, manufacturing, and other resources. Alkermes either purchases active drug products from third parties or receives them from its third-party licensees to formulate products using its technologies. It operates in U.S., which derives maximum revenue, Ireland and Rest of the world.
70GF Score
Get the complete analysis for ALKS
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ALKS has been successfully added to your 
